Possible Roles of Micro RNA‑142‑5p and Claudin-1 in Development of Hashimoto’s Thyroiditis in Iraqi Patients

Authors

  • Khaled Nather Taha College of Health & Medical Technology - Baghdad, Middle Technical University, Baghdad, Iraq
  • Farhan Abood Risan Institute of Medical Technology \ Mansour, Middle Technical University, Baghdad, Iraq.
  • Abdulameer Jasim Mohammed College of Health & Medical Technology - Baghdad, Middle Technical University, Baghdad, Iraq

DOI:

https://doi.org/10.51173/jt.v4i2.473

Keywords:

Autoimmune Diseases, Hashimoto’s Thyroiditis, Micro RNA, miR-142-5p, Claudin 1

Abstract

Background: Micro RNA 142-5p may one day be employed as diagnostic or therapeutic targets in the therapy of autoimmune diseases. The expression of microRNA142-5p in serum from newly diagnosed patients with Hashimoto's thyroiditis has only been studied in a few tissue cases. In addition, elevated microRNA142-5p in tissue is associated with reduced Claudin1 tissue expression in thyrocyte HT patients. This study tries to evaluate these findings in serum of HT before starting treatment. Methods: One hundred-twenty subjects enrolled in this study, divided into 40 newly diagnosed HT patients before treatment are classified into (Euthyroid HT, Subclinical HT, and Overt HT) based on thyroid function test presentation, 40 non-immune hypothyroidism, and 40 healthy controls. The possible mechanisms of microRNA-142-5p in Hashimoto's thyroiditis were investigated by measuring serum MicroRNA 142-5p by quantitative RT-PCR, in addition, to measuring serum Claudin1 by sandwich ELISA. Results: At the time of presentation, the outcome of the tests revealed that 12.5 percent of HT patients had euthyroidism, 30 percent had overt thyroiditis, and 57.5 percent had sub-clinical thyroiditis. miR-142-5p, that's been found to be expressed at significant levels in HT patient serum. Moreover, the ELISA test demonstrated serum Claudin1 was no significant difference between the studied groups. Conclusions: Our data suggest that micro RNA 142-5p may play a role in HT development and pathogenesis through an as-yet-unidentified mechanism, even though serum Claudin1 is not significantly affected in the serum of HT. Chemical thyroid function characteristics at the time of HT manifestation in adults are mostly influenced by the age of the patients and gender.

Downloads

Download data is not yet available.

Author Biography

Khaled Nather Taha, College of Health & Medical Technology - Baghdad, Middle Technical University, Baghdad, Iraq

طالب دكتوراه. قسم المختبرات الطبية ، كلية التقنيات الصحية والطبية ، الجامعة التقنية الوسطى ، بغداد ، العراق.

References

Capuzzo, A. M. (2021). Hashimoto's thyroiditis Autoimmune Disease: background and current status, update overview of Biotechnological and Biomedical fields, and future trends for 3D models.‏

Himanshu, S., Rahul, S., Naincy, P., Umesh, G., Sanjay, S., & Balram, S. (2022). Co-existence of type 1 diabetes and other autoimmune ailments in subjects with autoimmune thyroid disorders. Diabetes & Metabolic Syndrome: Clinical Research & Reviews, 102405.‏

Klubo-Gwiezdzinska, J., & Wartofsky, L. (2022). Hashimoto thyroiditis: an evidence-based guide: etiology, diagnosis, and treatment.Polish Archives of Internal Medicine.‏

Iborra, M., Bernuzzi, F., Invernizzi, P., & Danese, S. (2012). Micro RNA 142-5p in autoimmunity and inflammatory bowel disease: crucial regulators in the immune response. Autoimmunity Reviews, 11(5), 305–314.

Bernecker, C, Halim, F., Lenz, L., Haase, M., Nguyen, T., Ehlers, M., Vordenbaeumen, S., & Schott, M. (2014). microRNA expressions in CD4+ and CD8+ T-cell subsets in autoimmune thyroid diseases. Experimental and Clinical Endocrinology & Diabetes, 122(02), 107– 112.

Peng, H., Liu, Y., Tian, J., Ma, J., Tang, X., Yang, J., Rui, K., Zhang, Y., Mao, C., & Lu, L. (2015). Decreased expression of microRNA- 125a-3p upregulates interleukin-23 receptor in patients with Hashimoto’s thyroiditis. Immunologic Research, 62(2), 129–136.

Bernecker, Christian, Lenz, L., Ostapczuk, M. S., Schinner, S., Willenberg, H., Ehlers, M., Vordenbäumen, S., Feldkamp, J., & Schott,

M. (2012). Micro RNA 142-5p miR-146a1, miR-155_2, and miR-200a1 are regulated in autoimmune thyroid diseases. Thyroid, 22(12), 1294–1295.

Dorris, E. R., Smyth, P., O’Leary, J. J., & Sheils, O. (2012). MIR141 expression differentiates Hashimoto thyroiditis from PTC and benign thyrocytes in Irish archival thyroid tissues. Frontiers in Endocrinology, 3, 102. Nilsson, M., Husmark, J., Björkman, U., & Ericson, L. E. (1998). Cytokines and thyroid epithelial integrity: interleukin-1α induces dissociation of the junctional complex and paracellular leakage in filter-cultured human thyrocytes. The Journal of Clinical Endocrinology & Metabolism, 83(3), 945–952.

Zimmermann, M. B., Hess, S. Y., Molinari, L., De Benoist, B., Delange, F., Braverman, L. E., Fujieda, K., Ito, Y., Jooste, P. L., Moosa, K., Pearce, E. N., Pretell, E. A., & Shishiba, Y. (2004). New reference values for thyroid volume by ultrasound in iodine-sufficient schoolchildren: a World Health Organization/Nutrition for Health and Development Iodine Deficiency Study Group Report. The American journal of clinical nutrition, 79(2), 231–237.

Hanfush, A. S. (2010). Autoantibodies to thyroid peroxidase (Microsomal) and Thyroglobulin in IRAQI patients with thyroid disorders diagnosed by Immunofluorescence. A thesis submitted to the college of medicine, Baghdad University for an MSc in pathology/Immunology and Microbiology.

Peretianu, D. (2005). Antithyroperoxidase antibodies (ATPO) in Hashimoto thyroiditis: variation of levels and correlation with echographic patterns. Acta Endocrinologica (1841-0987), 1(1).

Manji, N., Carr-Smith, J. D., Boelaert, K., Allahabadia, A., Armitage, M., Chatterjee, V. K., Lazarus, J. H., Pearce, S. H. S., Vaidya, B., & Gough, S. C. (2006). Influences of age, gender, smoking, and family history on autoimmune thyroid disease phenotype. The Journal of Clinical Endocrinology & Metabolism, 91(12), 4873–4880.

Skarpa, V., Kousta, E., Tertipi, A., Anyfandakis, K., Vakaki, M., Dolianiti, M., Fotinou, A., & Papathanasiou, A. (2011). Epidemiological characteristics of children with autoimmune thyroid disease. Hormones (Athens, Greece), 10(3), 207–214.

Ghoraishian, S. M., Hekmati Moghaddam, S. H., & Afkhami-Ardekani, M. (2006). Relationship between Anti-Thyroid Peroxidase Antibody and Thyroid Function Test. Iranian Journal of Immunology : IJI, 3(3), 146–149.

de Vries, L., Bulvik, S., & Phillip, M. (2009). Chronic autoimmune thyroiditis in children and adolescents: at presentation and during long-term follow-up. Archives of disease in childhood, 94(1), 33–37.

Gopalakrishnan, S., Chugh, P. K., Chhillar, M., Ambardar, V. K., Sahoo, M., & Sankar, R. (2008). Goitrous autoimmune thyroiditis in a pediatric population: a longitudinal study. Pediatrics, 122(3), e670-e674.

Svensson, J., Ericsson, U. B., Nilsson, P., Olsson, C., Jonsson, B., Lindberg, B., & Ivarsson, S. A. (2006). Levothyroxine treatment reduces thyroid size in children and adolescents with chronic autoimmune thyroiditis. The Journal of Clinical Endocrinology & Metabolism, 91(5), 1729-1734.‏

Teresa, Z., & Golenko, A. (2005). Chronic autoimmune thyroid disease in children and adolescents in the years 1999-2004 in Lower Silesia, Poland. Hormones, 4(1), 45-48.‏

Livak, K. J., & Schmittgen, T. D. (2001). Analysis of relative gene expression data using real-time quantitative PCR and the 2− ΔΔCT method. methods, 25(4), 402-408.‏

Özen, S., Berk, Ö., Şimşek, D. G., & Darcan, S. (2011). The clinical course of Hashimoto's thyroiditis and effects of levothyroxine therapy on the clinical course of the disease in children and adolescents. Journal of clinical research in pediatric endocrinology, 3(4), 192–197.

Skarpa, V., Kousta, E., Tertipi, A., Anyfandakis, K., Vakaki, M., Dolianiti, M., Fotinou, A., & Papathanasiou, A. (2011). Epidemiological characteristics of children with autoimmune thyroid disease. Hormones (Athens, Greece), 10(3), 207–214.

Ceribelli, A., Satoh, M., & Chan, E. K. L. (2012). Micro RNA 142-5p and autoimmunity. Current Opinion in Immunology, 24(6), 686– 691.

Dai, R., & Ahmed, S. A. (2011). MicroRNA, a new paradigm for understanding immunoregulation, inflammation, and autoimmune diseases. Translational Research, 157(4), 163–179.

Hu, R., & O’Connell, R. M. (2013). MicroRNA control in the development of systemic autoimmunity. Arthritis Research & Therapy, 15(1), 1–9.

Ding, S., Liang, Y., Zhao, M., Liang, G., Long, H., Zhao, S., Wang, Y., Yin, H., Zhang, P., & Zhang, Q. (2012). Decreased microRNA‐ 142‐3p/5p expression causes CD4+ T cell activation and B cell hyperstimulation in systemic lupus erythematosus. Arthritis & Rheumatism, 64(9), 2953–2963.

Ando, Y., Yang, G.-X., Kenny, T. P., Kawata, K., Zhang, W., Huang, W., Leung, P. S. C., Lian, Z.-X., Okazaki, K., & Ansari, A. A. (2013). Overexpression of microRNA-21 is associated with elevated pro-inflammatory cytokines in dominant-negative TGF-β receptor type II mouse. Journal of Autoimmunity, 41, 111–119.

Wang, G., Tam, L. S., Li, E. K. M., Kwan, B. C. H., Chow, K. M., Luk, C. C. W., Li, P. K. T., & Szeto, C. C. (2011). Serum and urinary free microRNA level in patients with systemic lupus erythematosus. Lupus, 20(5), 493–500.

Gandhi, R., Healy, B., Gholipour, T., Egorova, S., Musallam, A., Hussain, M. S., Nejad, P., Patel, B., Hei, H., & Khoury, S. (2013). Circulating micro RNA 142-5p as biomarkers for disease staging in multiple sclerosis. Annals of Neurology, 73(6), 729–740.

Mitchell, P. S., Parkin, R. K., Kroh, E. M., Fritz, B. R., Wyman, S. K., Pogosova-Agadjanyan, E. L., Peterson, A., Noteboom, J., O’Briant, K. C., & Allen, A. (2008). Circulating micro RNA 142-5p as stable blood-based markers for cancer detection. Proceedings of the National Academy of Sciences, 105(30), 10513–10518.

Yamamichi, N., Shimomura, R., Inada, K., Sakurai, K., Haraguchi, T., Ozaki, Y., Fujita, S., Mizutani, T., Furukawa, C., & Fujishiro, M. (2009). Locked nucleic acid in situ hybridization analysis of miR-21 expression during colorectal cancer development. Clinical Cancer Research, 15(12), 4009–4016.

Michael, M. Z., O’Connor, S. M., van Holst Pellekaan, N. G., Young, G. P., & James, R. J. (2003). Reduced Accumulation of Specific Micro RNA 142-5p in Colorectal Neoplasia11Note: Susan M. O’Connor and Nicholas G. van Holst Pellekaan contributed equally to this work. Molecular Cancer Research, 1(12), 882–891.

Merkerova, M., Belickova, M., & Bruchova, H. (2008). Differential expression of micro RNA 142-5p in hematopoietic cell lineages. European of Journal Haematology, 81(4), 304–310.

Collares, C. V. A., Evangelista, A. F., Xavier, D. J., Rassi, D. M., Arns, T., Foss-Freitas, M. C., Foss, M. C., Puthier, D., Sakamoto-Hojo, E. T., &Passos, G. A. (2013). Identifying common and specific micro RNA 142-5p expressed in peripheral blood mononuclear cells of type 1, type 2, and gestational diabetes mellitus patients. BMC Research Notes, 6(1), 1–15.

Chaudhuri, A. D., Yelamanchili, S. V, Marcondes, M. C. G., & Fox, H. S. (2013). Up‐regulation of microRNA‐142 in simian immunodeficiency virus encephalitis leads to repression of sirtuin1. The FASEB Journal, 27(9), 3720–3729.

Kee, H. J., Park, S., Kwon, J.-S., Choe, N., Ahn, Y., Kook, H., & Jeong, M. H. (2013). B cell translocation gene, a direct target of miR- 142-5p, inhibits vascular smooth muscle cell proliferation by down-regulating cell cycle progression. FEBS Letters, 587(15), 2385–2392.

Furuse, M., Fujita, K., Hiiragi, T., Fujimoto, K., & Tsukita, S. (1998). Claudin-1 and-2: novel integral membrane proteins localizing at tight junctions with no sequence similarity to occludin. The Journal of Cell Biology, 141(7), 1539–1550.

Günzel, D., & Yu, A. S. L. (2013). Claudins and the modulation of tight junction permeability. Physiological Reviews, 93(2), 525–569.

D’Aversa, T. G., Eugenin, E. A., Lopez, L., & Berman, J. W. (2013). Myelin basic protein induces inflammatory mediators from primary human endothelial cells and blood-brain barrier disruption: implications for the pathogenesis of multiple sclerosis. Neuropathology and Applied Neurobiology, 39(3), 270–283.

Zhu, J., Zhang, Y., Zhang, W., Zhang, W., Fan, L., Wang, L., Liu, Y., Liu, S., Guo, Y., & Wang, Y. (2016). MicroRNA-142-5p contributes to Hashimoto’s thyroiditis by targeting CLDN1. Journal of Translational Medicine, 14(1), 1–13.

Downloads

Published

2022-06-30

How to Cite

Taha, K. N. ., Risan, F. A. ., & Mohammed, A. J. . (2022). Possible Roles of Micro RNA‑142‑5p and Claudin-1 in Development of Hashimoto’s Thyroiditis in Iraqi Patients. Journal of Techniques, 4(2), 50–55. https://doi.org/10.51173/jt.v4i2.473

Issue

Section

Medical techniques

Similar Articles

1 2 3 > >> 

You may also start an advanced similarity search for this article.